A growing tide of clinical research is transforming synovial sarcoma treatment prospects. According to DelveInsight Business Research LLP, over 15 pharmaceutical firms are developing more than 20 new therapies, reflecting a heightened commitment to tackling this rare cancer.

A new report highlights more than 75 drugs under consideration for Duchenne muscular dystrophy, promising significant progress in patient care. The analysis explores clinical strategies, upcoming therapies, and commercial prospects, signaling a major shift in the DMD landscape.